Cyclana Bio is a Cambridge‑based biotech startup on a mission to revolutionize women’s health by developing treatments that begin at the tissue–rather than single‑cell–level. The interdisciplinary team is building first‑of‑its‑kind physiological assays of the tissue niche, powered by donated menstrual fluid, to model conditions like Endometriosis in environments that closely mimic how they behave in the human body. By integrating epigenetics, cell signalling and the extracellular matrix, they aim to better stratify women’s health conditions, uncover novel drug targets and close long‑standing gaps in therapeutic discovery.